IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF FLORIDA
TALLAHASSEE DIVISION

AUGUST DEKKER, *et al.*, *Plaintiffs*, v. JASON WEIDA, *et al.*, *Defendants*.	Case No. 4:22-cv-325-RH-MAF

JOINT PRETRIAL STIPULATIONS

Plaintiffs August Dekker, Brit Rothstein, Susan Doe, Jane Doe, John Doe and K.F., by and through his parent and next friend, Jade Ladue, and Defendants Jason Weida and the Florida Agency for Health Care Administration ("AHCA"), jointly submit this Pretrial Stipulation pursuant to the Court's Scheduling Order dated November 15, 2022 [ECF No. 67].

I. Basis of Federal Jurisdiction

The parties agree this Court has subject matter jurisdiction pursuant to 28 U.S.C. § 1331 because the action arises under the Constitution and the laws of the United States.

II. Brief General Statement of Each Party's Case

A. Plaintiffs' Statement

Empirical evidence and decades of clinical experience demonstrate that medical care for the treatment of gender dysphoria, also known as gender-affirming care, is medically necessary, safe, and effective for both transgender adolescents and adults with gender dysphoria. Gender-affirming care is neither experimental nor investigational; it is the prevailing standard of care, accepted and supported by every major medical organization in the United States.

Until August 2022, AHCA provided Medicaid coverage for gender-affirming care, including puberty-delaying medications, hormone therapy, and gender-affirming surgeries, for adolescents and adults for whom it was medically necessary to treat gender dysphoria. Between 2017 and 2021 alone, AHCA covered over 6,000 prescriptions for hormone therapy; covered at least 67 surgeries to treat gender dysphoria during that time; and covered over 405 prescriptions for puberty-delaying medications.

In August 2022, amidst a wave of anti-LGBTQ laws supported by Governor DeSantis, including but not limited to the "Don't Say Gay or Trans" laws and policies restricting access to gender-affirming care, AHCA reversed its prior practice and promulgated a rule that categorically banned coverage for all medical treatments intended to treat gender dysphoria. The change in policy did

not stem from a concern over the efficacy or necessity of gender-affirming care. Indeed, AHCA had already determined that some this of care was effective and safe, and had covered it as necessary for thousands of transgender Medicaid beneficiaries. The change was fueled by animus against transgender people and political opportunism to wage a social issue war based on the Biden Administration's position in favor of gender-affirming care. The Office of Governor DeSantis instructed AHCA and the Florida Department of Health ("FDOH") to create a policy against this care.

In April 2022, the FDOH issued a set of guidelines titled "Treatment of Gender Dysphoria for Children and Adults." The FDOH Guidelines recommended against prescribing puberty-delaying medication and hormone treatments to children and adolescents, and even counseled against allowing minors to socially transition. Simultaneously, AHCA formally initiated a review of gender-affirming care called a GAPMS review that was already in the works after a directive from the Governor. Through this process AHCA determined that gender-affirming medical care does not conform to GAPMS ("generally accepted professional medical standards") and is experimental and investigational, notwithstanding a multitude of studies and decades of clinical experience documenting the necessity, safety, and efficacy of this care. Based on the review, and the GAPMS Report generated by the review, AHCA

proposed its categorical ban on gender-affirming care in June 2022, which was adopted verbatim in August 2022 ("Challenged Exclusion").

The evidence shows that the GAPMS process was a farse intended to further the Governor's political agenda against gender-affirming care and the transgender community. Indeed, the review was based on AHCA's unprecedented hiring of outside consultants to assist in the GAPMS process, and only considered the views of opponents of gender-affirming care, who represent extreme outliers within the overwhelming consensus of major medical organizations and health care professionals who actually treat and study gender dysphoria and transgender care. The findings in GAPMS Report are not reasonable based on current medical knowledge. See Rush v. Parham, 625 F.2d 1150 (5th Cir. 1980).

Separately, the Challenged Exclusion violates various provisions of the Medicaid Act and the U.S. Constitution. First, the Challenged Exclusion violates the Medicaid Act's EPSDT requirements because it denies coverage of medically necessary treatments for Medicaid beneficiaries under the age of 21. Second, the Challenged Exclusion violates the Medicaid Act's comparability requirements because it only denies coverage when the specific treatment is used to treat gender dysphoria. Coverage is still available when the treatment is used for other indications. Third, the Challenged Exclusion violates Section 1557 of

the Affordable Care Act because it discriminates against Plaintiffs based on their sex, including sex stereotypes and beneficiaries' transgender status. Fourth, the Challenged Exclusion violates the Equal Protection Clause of the U.S. Constitution because it facially discriminates based on sex and transgender status, was otherwise enacted for purposeful discrimination, and reflects a bare desire to harm transgender people.

Defendants' Statement

This case is about the State of Florida's policy choice, backed by evidence-based science, to deny Medicaid reimbursement for certain treatments for gender dysphoria. That choice was reasonable, constitutional, and statutorily permissible: the treatments are experimental. In making this decision, the State joins the ranks of countries—Sweden, Finland, Norway, the United Kingdom, France, Australia, and New Zealand—that urge caution when offering these treatments.

III. Witness List

Plaintiffs' witness list is attached to this Pretrial Stipulation as Appendix [1]. Defendants' witness list is attached to this Pretrial Stipulation as Appendix [2].

IV. Exhibit Lists

Plaintiffs' exhibit list is attached to this Pretrial Stipulation as Appendix

[3]. Defendants' exhibit list is attached to this Pretrial Stipulation as Appendix [4].

V. Stipulations of Fact and Agreement on Issues

1. Each Plaintiff received health coverage through Florida's Medicaid program as of October 2022.

2. Prior to the enactment of the Challenged Exclusion, Florida Medicaid covered certain treatments of gender dysphoria.

A. Florida Medicaid

3. The State of Florida participates in the federal Medicaid program. AHCA is the single state agency in Florida that is responsible for administering and implementing Florida's Medicaid program consistent with the requirements of federal law.

4. AHCA receives federal financial assistance from the U.S. Department of Health and Human Services ("HHS"), including through the federal Medicaid program.

5. To qualify as medically necessary, a service must meet all the conditions set out in section 2.83 of Fla. Admin. Code R. 59G-1.010.

6. One of the conditions to be met under section 2.83 is that the service must be consistent with generally accepted professional medical standards and not experimental or investigational.

7. To determine whether a particular service is consistent with generally accepted professional medical standards, AHCA must consider: (a) Evidence-based clinical practice guidelines; (b) Published reports and articles in the authoritative medical and scientific literature related to the health service (published in peer-reviewed scientific literature generally recognized by the relevant medical community or practitioner specialty associations); (c) Effectiveness of the health service in improving the individual's prognosis or health outcomes; (d) Utilization trends; (e) Coverage policies by other creditable insurance payor sources; (f) Recommendations or assessments by clinical or technical experts on the subject or field.

8. After considering those factors, AHCA must submit a report with recommendations to the Deputy Secretary for Medicaid for review.

9. The Deputy Secretary makes a final determination as to whether the health service is consistent with generally accepted professional medical standards and not experimental or investigational.

B. Gender Dysphoria and the June 2022 GAPMS Report on the Treatment of Gender Dysphoria

10. Gender dysphoria is a diagnosis contained in the American Psychiatric Association's *Diagnostic and Statistical Manual of Mental Disorders, 5th Edition* ("DSM-5").

11. On March 2, 2022, HHS issued guidance on gender-affirming care ("HHS Guidance").

12. HHS issued an additional factsheet on gender-affirming care later that month ("HHS Factsheet").

13. AHCA retained seven individuals to assist with its determination regarding coverage for gender-affirming care: Dr. Miriam Grossman, Dr. Andre Van Mol, Dr. Romina Brignardello-Petersen, Dr. James Cantor, Dr. Quentin Van Meter, Dr. Patrick Lappert, and Dr. G. Kevin Donovan.

14. On April 20, 2022, the FDOH issued a set of guidelines titled "Treatment of Gender Dysphoria for Children and Adults" ("FDOH Guidelines").

15. The FDOH issued the FDOH Guidelines in response to guidance issued by HHS.

16. The FDOH Guidelines stated that:

a. Social gender transition should not be a treatment option for children or adolescents;

b. Anyone under 18 should not be prescribed puberty delaying medication or hormone therapy; and

c. Gender reassignment surgery should not be a treatment option for children or adolescents.

17. On April 20, 2022, then-Secretary Simone Marstiller sent a letter to Tom Wallace, AHCA's Deputy Secretary for Medicaid, requesting that AHCA determine if the treatments addressed in the FDOH Guidelines "are consistent with generally accepted professional medical standards and not experimental or investigational."

18. When medically necessary to treat a condition other than gender dysphoria, Florida Medicaid covers puberty-delaying medication, hormone antagonists, mastectomies, reduction mammoplasties, and breast reduction surgeries; hysterectomies and oophorectomy procedures; vaginoplasty procedures; orchiectomy, penectomy, and phalloplasty.

19. On or about April 20, 2022, AHCA formally tasked Matthew Brackett with conducting the GAPMS review of gender-affirming care, with assistance from two AHCA employees Devona Pickle and Nai Chen.

20. At the time, Brackett, Pickle and Chen were part of the Canadian Prescription Drug Importation Plan team.

21. AHCA retained Drs. Van Mol and Grossman as outside consultants to assist with the GAPMS process.

22. While Brackett was conducting the GAPMS review, the five other consultants hired by AHCA— Dr. Romina Brignardello-Petersen, Dr. James Cantor, Dr. Quentin Van Meter, Dr. Patrick Lappert, and Dr. G. Kevin

Donovan—drafted their own reports.

23. On June 2, 2022, Defendants published their report, "Florida Medicaid: Generally Accepted Professional Medical Standards Determination on the Treatment of Gender Dysphoria" (hereinafter "GAPMS Report").

24. The GAPMS Report concluded that gender-affirming medical treatments, including puberty blockers, hormone therapy, and surgery "do not conform to GAPMS [("generally accepted professional medical standards")] and are experimental and investigational."

C. The Challenged Exclusion

25. On June 17, 2022, AHCA issued a Notice of Proposed Rule seeking to amend Florida Administrative Code 59G-1.050 to prohibit Florida Medicaid from covering "services for the treatment of gender dysphoria," including: "1. Puberty blockers; 2. Hormones and hormone antagonists; 3. Sex reassignment surgeries; and 4. Any other procedures that alter primary or secondary sexual characteristics."

26. The Proposed Rule also stated that, "For the purpose of determining medical necessity, including Early and Periodic Screening, Diagnosis, and Treatment (EPSDT)," the aforementioned services "do not meet the definition of medical necessity in accordance with Rule 59G-1.010, F.A.C."

27. On July 8, 2022, AHCA held a public hearing on the proposed rule.

28. AHCA hired Dr. Andre Van Mol, Dr. Quentin Van Meter and Dr. Miriam Grossman to participate in the public hearing as panelists.

29. The individuals who participated in the July 8 hearing included AHCA employees Jason Weida, Cole Gearing, Matt Brackett and Shena Grant.

30. Defendants filed the Challenged Exclusion as a final rule for adoption on August 1, 2022.

31. Notice of the Final Adopted Version of the Challenged Exclusion was published on FLRules.com on August 10, 2022 and stated that the Challenged Exclusion would become effective on August 21, 2022.

32. The Challenged Exclusion, in its final adopted form within Florida Administrative Code 59G-1.050, states as follows:

> (7) Gender Dysphoria.
>
> (a) Florida Medicaid does not cover the following services for the treatment of gender dysphoria:
>
> 1. Puberty blockers;
>
> 2. Hormones and hormone antagonists;
>
> 3. Sex reassignment surgeries; and
>
> 4. Any other procedures that alter primary or secondary sexual characteristics.

33. Coverage for each of the four services listed within the Challenged

Exclusion is still available when those services are medically necessary for the treatment of a condition other than gender dysphoria.

VI. Statement of Factual Issues to be Litigated

A. Plaintiffs' Statement of Factual Issues to be Litigated

1. The Defendants' Challenged Exclusion targets transgender Medicaid beneficiaries, including Plaintiffs August Dekker, Brit Rothstein, Susan Doe, and K.F., by excluding from Medicaid coverage the medically necessary treatments for their gender dysphoria.

2. At the request of the Governor and FDOH, AHCA initiated a biased GAPMS process to review treatments for gender-affirming care.

3. The GAPMS process was a farse intended to further the Governor's political agenda against gender-affirming care and the transgender community.

4. Defendants determined the outcome of the review process before it began.

5. The GAPMS Process was a pretextual means by which to eliminate Medicaid coverage for care that only transgender people.

6. Documents produced in discovery by the Office of the Surgeon General demonstrate the planned "pathway" laid out for the strategic exclusion of gender-affirming healthcare in Florida. One flow chart illustrated the steps between step 1, "Surgeon General issues guidance on Gender Dysphoria" to step

6, "AHCA Contract Amendments/Care Effectively Banned." Another flow chart illustrated the strategic plan, beginning with the "Surgeon General Issues Guidance" in April, 2022, followed by the GAPMS process in April-early June 2022, followed by a "Legislative Proposal Announced Following AHCA Report" and "Rulemaking" by the Boards of Medicine, Osteopathic Medicine, Psychiatry, and Psychology, followed by rulemaking June-September 2022 concluding with "AHCA Contract Amendments/Care Effective Banned."

7. Defendants instructed the drafter of the GAPMS Report, Matthew Brackett, to produce a report that would support a categorical ban on Medicaid coverage of treatments for gender dysphoria.

8. The consultants hired by AHCA for purposes of the GAPMS process—namely, Dr. Grossman, Dr. Van Mol, Dr. Van Meter, Dr. Donovan, Dr. Cantor, Dr. Brignardello-Petersen and Dr. Lappert—were chosen because of their opposition to gender-affirming care.

9. Defendants were connected with the consultants they hired through Michelle Cretella, the Executive Director of the American College of Pediatricians (ACPeds), an organization that has been designated as a hate group due to its anti-LGBTQ+ positions.

10. Dr. Van Mol provided AHCA with a document that served as a first draft of the GAPMS Report.

11. In drafting the GAPMS Report, Defendants did not properly consider all the factors that it was required to consider under Fla. Admin. Code R. 59G-1.035.

12. Once the report was written, it was not properly reviewed by Agency leadership but instead was quickly signed off on within 24 hours.

13. The June 2022 GAPMS Report does not present an honest and accurate assessment of the status of the current evidence and practice guidelines.

14. Empirical evidence and decades of clinical experience demonstrate that medical care for the treatment of gender dysphoria is medically necessary, safe, and effective for both transgender adolescents and adults with gender dysphoria.

15. Medical treatment for gender dysphoria, including puberty-delaying medications, hormones, and surgery, is neither experimental nor investigational.

16. Gender-affirming care is the prevailing standard of care, accepted and supported by every major medical organization in the United States.

17. Medical treatment for gender dysphoria, including puberty-delaying medications, hormones, and surgery, is safe.

18. Medical treatment for gender dysphoria, including puberty-delaying medications, hormones, and surgery, is effective in treating a person's

gender dysphoria.

19. Gender-affirming care has been documented to improve the mental health, wellbeing, and overall quality of life of transgender people with gender dysphoria.

20. By denying coverage for medical treatment for gender dysphoria, Defendants effectively categorically deny access to medically necessary care to thousands of Floridians who lack other means to pay for such care.

21. Defendants' actions come within the context of a series of measures the State has adopted targeting transgender people for discrimination.

22. Defendants' actions stand in sharp contrast not just to the well-established evidence and widely accepted view of the medical and scientific community in the United States, but also to the policies of the vast majority of states, which provide Medicaid coverage for gender-affirming care.

23. If allowed to remain in effect, the Challenged Exclusion will have dire physical, emotional, and psychological consequences for transgender Medicaid beneficiaries.

24. Defendants purposefully targeted transgender people for discrimination.

25. Defendants provide coverage for the same puberty-delaying medications, hormones, and surgery when used to treat conditions other than

gender dysphoria.

26. By enforcing the Challenged Exclusion, Defendants treat transgender Medicaid beneficiaries differently than other Medicaid beneficiaries.

27. The safety profile of puberty-medications, hormones, and surgery is the same regardless of whether it is used to treat gender dysphoria.

B. Defendants' Statement of Factual Issues to be Litigated

1. "[W]hether, based on current medical knowledge, the state's determination that" the excluded treatments "are experimental is reasonable." ECF No. 64 at 4.

VII. Statement of Legal Issues for Determination by the Court

1. Whether, based on current medical knowledge, the Defendants' determination that certain gender-affirming medical treatments, including puberty-delaying medications, hormones, and surgery, are experimental is reasonable.

2. Whether Defendants, by promulgating the Challenged Exclusion, have discriminated against Plaintiffs on the basis of sex in violation of Section 1557.

3. Whether Defendants, by promulgating the Challenged Exclusion, have discriminated against Plaintiffs in violation of the Fourteenth Amendment

of the U.S. Constitution.

4. Whether Defendants, by promulgating the Challenged Exclusion, have wrongfully denied necessary Medicaid services to Plaintiffs Brit Rothstein, Susan Doe and K.F. in violation of the EPSDT provisions of the Medicaid Act, 42 U.S.C. §§ 1396a(a)(10)(A), 1396a(a)(43)(C), 1396d(a)(4)(B), and 1396d(r).

5. Whether Defendants, by promulgating the Challenged Exclusion, which denies coverage for services for the treatment of gender dysphoria while covering the same services to treat different diagnoses, violate the Medicaid Act's comparability requirements, 42 U.S.C. § 1396a(10)(B)(i).

VIII. Statement of any Disagreement on Admissibility of Evidence and Application of Federal Rules of Procedure or Evidence

The parties' respective objections to certain exhibits are set forth on the Exhibit Lists attached to this Pretrial Stipulation. Other evidentiary issues may be presented in the parties' motion *in limine*. The parties have no other known disagreements regarding the admissibility of evidence or application of the Federal Rules of Procedure or Evidence.

IX. Motions that Remain Pending

The motions that remain pending are as follows:

1. Plaintiffs' Motion to Exclude Expert Testimony of Sophie Scott, Ph.D. (ECF No. 119);

2. Plaintiffs' Motion to Partially Exclude Expert Testimony of Dr. Patrick Lappert (ECF No. 127);

3. Plaintiffs' Motion to Exclude Expert Testimony of Michael Biggs, Ph.D. (ECF No. 128);

4. Plaintiffs' Motion to Exclude Expert Testimony of Michael Laidlaw (ECF No. 133);

5. Plaintiffs' Unopposed Motion to Seal (ECF No. 135);

6. Plaintiffs' Motion to Exclude Expert Testimony of Dr. Paul Hruz (ECF No. 136);

7. Plaintiffs' Motion to Exclude Expert Testimony Dr. Kristopher Kaliebe (ECF Nos. 138, 139);

8. Plaintiffs' Motion to Exclude Expert Testimony of Stephen B. Levine, M.D. (ECF No. 141, 145);

9. Plaintiffs' Motion to Exclude Expert Testimony of Joseph Zanga M.D. (ECF No. 142);

10. Plaintiffs' Motion to Exclude Expert Testimony of Dr. Quentin Van Meter (ECF No. 143, 144);

11. Defendants' Motion for Summary Judgment (ECF No. 120);

12. Defendants' Omnibus Motion in Limine (ECF No. 124);

13. Consent Motion to Seal Certain Trial Exhibits (ECF No. 174);

14. Plaintiffs' Motion *in Limine* Regarding Pronoun Usage and Misgendering (ECF No. 187);

15. Defendants' Motion to Exclude Fact Witness (ECF No. 194);

16. Plaintiffs' Request for Judicial Notice (forthcoming)

X. Estimated Length of Trial

The parties estimate that trial of this matter will require a total of ten (10) trial days.

Dated: April 28, 2023

Respectfully submitted for Plaintiffs,

/s/ Gary J. Shaw

PILLSBURY WINTHROP SHAW PITTMAN, LLP

Jennifer Altman (Fl. Bar No. 881384)
Shani Rivaux (Fl. Bar No. 42095)
600 Brickell Avenue, Suite 3100
Miami, FL 33131
(786) 913-4900
jennifer.altman@pillsbury.com
shani.rivaux@pillsbury.com

William C. Miller*
Gary J. Shaw*
1200 17th Street N.W.
Washington, D.C. 20036
(202) 663-8000

LAMBDA LEGAL DEFENSE AND EDUCATION FUND, INC.

Omar Gonzalez-Pagan*
120 Wall Street, 19th Floor
New York, NY 10005
(212) 809-8585
ogonzalez-pagan@lambdalegal.org

Carl S. Charles*
1 West Court Square, Suite 105
Decatur, GA 30030
(404) 897-1880
ccharles@lambdalegal.org

SOUTHERN LEGAL COUNSEL, INC.

william.c.miller@pillsburylaw.com

Joe Little*
500 Capitol Mall, Suite 1800
Sacramento, CA 95814
(916) 329-4700
joe.little@pillsburylaw.com

NATIONAL HEALTH LAW PROGRAM

Abigail Coursolle*
3701 Wilshire Boulevard, Suite 315
Los Angeles, CA 90010
(310) 736-1652
coursolle@healthlaw.org

Catherine McKee*
1512 E. Franklin Street, Suite 110
Chapel Hill, NC 27541
(919) 968-6308
mckee@healthlaw.org

Simone Chriss (Fl. Bar No. 124062)
Chelsea Dunn (Fl. Bar No. 1013541)
1229 NW 12th Avenue
Gainesville, FL 32601
(352) 271-8890
Simone.Chriss@southernlegal.org
Chelsea.Dunn@southernlegal.org

FLORIDA HEALTH JUSTICE PROJECT

Katy DeBriere (Fl. Bar No. 58506)
3900 Richmond Street
Jacksonville, FL 32205
(352) 278-6059
debriere@floridahealthjustice.org

* *Admitted pro hac vice*
Counsel for Plaintiffs

Respectfully submitted for Defendants,

/s/ Mohammad O. Jazil
Mohammad O. Jazil (FBN: 72556)
Gary V. Perko (FBN: 855898)
Michael Beato (FBN: 1017715)
HOLTZMAN VOGEL BARAN
TORCHINSKY & JOSEFIAK PLLC
119 S. Monroe St. Suite 500
Tallahassee, FL 32301
mjazil@holtzmanvogel.com
gperko@holtzmanvogel.com
mbeato@holtzmanvogel.com
Phone No.: (850) 274-1690
Fax No.: (540) 341-8809

Counsel for Defendants Secretary Weida and Florida Agency for Healthcare Administration

CERTIFICATE OF SERVICE

I hereby certify that a true and correct copy of the foregoing and the documents referenced therein were served by email on April 28, 2023, on all counsel of record:

Mohammad O. Jazil (FBN 72556)
Gary V. Perko (FBN 855898)
Michael Beato (FBN 1017715)
mjazil@holtzmanvogel.com
gperko@holtzmanvogel.com
mbeato@holtzmanvogel.com
HOLTZMAN VOGEL BARANTORCHINSKY & JOSEFIAK PLLC
119 S. Monroe St., Suite 500
Tallahassee, FL 32301

COUNSEL FOR DEFENDANTS

/s/ Gary J. Shaw
ATTORNEY FOR PLAINTIFFS

APPENDIX 1

Plaintiffs' Witness List

Witness	Will Call	May Call	Deposition
August Dekker	X		
Brith Rothstein	X		
Jade Ladue	X		
Jane Doe	X		
John Doe		X	
Jeffrey English	X		
Ann Dalton			X[1]
Matthew Brackett			X[2]
Dr. Armand H. Antommaria	X		
Kellan E. Baker, M.A., M.P.H., PhD	X		
Dr. Dan H. Karasic	X		
Dr. Johanna Olson-Kennedy	X		

[1] Plaintiffs will enter the designated portions of Ms. Dalton's deposition transcript dated January 24, 2023 if Defendant does not call her to testify.

[2] Plaintiffs will enter the designated portions of Mr. Brackett's deposition transcripts dated February 8, 2023 and March 8, 2023 if Defendant does not call him to testify.

Dr. Loren S. Schechter	X		
Dr. Daniel Shumer	X		
Dr. E. Kale Edmiston	X		
Dr. Aron Janssen	X		
Denise Brogan-Kator	X		
Records Custodian		X	
Kim Hutton		X	

APPENDIX 2

Defendants' Witness List

Witness	Will Call	May Call	Deposition
Matthew Brackett	X		
Ann Dalton	X		
Dr. Stephen Levine	X		
Dr. Paul Hruz	X		
Dr. Sophie Scott	X		
Dr. Patrick Lappert	X		
Dr. Kristopher Kaliebe	X		
Dr. Michael Laidlaw		X	
Dr. Quentin Van Meter		X	
Dr. Joseph Zanga		X	

APPENDIX 3

Plaintiffs' Exhibit List

Trial Ex. No.	Bates No.	Exhibit Description	Will Use	May Use	Stipulated/ Defendants' Objections
Pls' Trial Ex. 1	PLAINTIFF S002191	Defendants' Response to Pls' First Set of Request for Admissions	X		No Objections
Pls' Trial Ex. 2	PLAINTIFF S002223	Defendants' Response to Pls' First Set of Interrogatories	X		No Objections
Pls' Trial Ex. 3	PLAINTIFF S002211	Defendants' Response to Pls' Second Set of Interrogatories		X	No Objections
Pls' Trial Ex. 4	PLAINTIFF S004943	Pls' First Set of Request for Admissions	X		No Objections
Pls' Trial Ex. 5	PLAINTIFF S002567	Expert report of Dr. Armand H. Antommaria – 2/16/2023		X	Objection: Hearsay
Pls' Trial Ex. 6	PLAINTIFF S002922	Expert report of Kellan E. Baker, M.A., M.P.H., PhD – 2/17/2023		X	Objection: Hearsay, Relevance
Pls' Trial Ex. 7	PLAINTIFF S002638	Expert report of Dr. Dan H. Karasic – 2/15/2023		X	Objection: Hearsay
Pls' Trial Ex. 8	PLAINTIFF S002706	Expert report of Dr. Johanna Olson-Kennedy – 2/16/2023		X	Objection: Hearsay
Pls' Trial Ex. 9	PLAINTIFF S007480	Expert report of Dr. Daniel Shumer – 2/16/2023		X	Objection: Hearsay
Pls' Trial Ex. 10	PLAINTIFF S002811	Expert report of Dr. Loren S. Schecter – 2/16/2023		X	Objection: Hearsay
Pls' Trial Ex. 11	PLAINTIFF S002293	Expert rebuttal report of Dr. Dan H. Karasic – 3/9/2023		X	Objection: Hearsay
Pls' Trial Ex. 12	PLAINTIFF S002332	Expert rebuttal report of Dr. Johanna Olson-Kennedy – 3/9/2023		X	Objection: Hearsay

Pls' Trial Ex. 13	PLAINTIFF S002389	Expert rebuttal report of Dr. Loren S. Schechter – 3/9/2023		X	Objection: Hearsay
Pls' Trial Ex. 14	PLAINTIFF S002406	Expert rebuttal report of Dr. Armand H. Antommaria – 3/10/2023		X	Objection: Hearsay
Pls' Trial Ex. 15	PLAINTIFF S002245	Corrected expert rebuttal report of Dr. E. Kale Edmiston – 3/22/2023		X	Objection: Hearsay
Pls' Trial Ex. 16	PLAINTIFF S002518	Expert rebuttal report of Dr. Daniel Shumer – 3/10/2023		X	Objection: Hearsay
Pls' Trial Ex. 17	PLAINTIFF S002446	Expert rebuttal report of Dr. Aron Janssen – 3/9/2023		X	Objection: Hearsay
Pls' Trial Ex. 18	PLAINTIFF S001297	AHCA GAPMS June 2022	X		Objection: Lack of Foundation, All Attachments Not Included
Pls' Trial Ex. 19	PLAINTIFF S004646	Marstiller Letter to Wallace re AHCA June 2022 GAPMS	X		No Objections
Pls' Trial Ex. 20	PLAINTIFF S001171	Fla. Admin. Code R. 59G-1.050	X		No Objections
Pls' Trial Ex. 21	PLAINTIFF S001157	Fla. Admin. Code R. 59G-1.010		X	Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 22	PLAINTIFF S001158	Florida Medicaid Definitions Policy (Aug. 2017)		X	Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 23	PLAINTIFF S001170	Fla. Admin. Code R. 59G-1.035	X		No Objections
		AHCA's Preferred Drug List, accessible at: https://ahca.myflorida.com/content/download/8681/file/PDL.pdf (online only); including but not limited to	X		No Objections

		the criteria for testosterone: https://ahca.myflorida.com/content/download/6451/file/Testosterone_Criteria.pdf			
		AHCA's Drug Criteria, accessible at: https://ahca.myflorida.com/medicaid/prescribed-drugs/drug-criteria (online only)	X		No Objections
Pls' Trial Ex. 24	PLAINTIFF S001347	AHCA's Automated Prior Authorizations and Bypass Lists 01-2023	X		Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 25	PLAINTIFF S003653	DRUGDEX listing for Testosterone	X		No Objections
Pls' Trial Ex. 26	PLAINTIFF S003383	DRUGDEX listing for Estradiol	X		No Objections
Pls' Trial Ex. 27	PLAINTIFF S001155	Prior Authorization Criteria - Testosterone		X	Objection: Authentication, Lack of Foundation, Relevance
Pls' Trial Ex. 28	PLAINTIFF S001283	Agency Responses to Plaintiffs' Questions: March 1, 2023	X		Objection: Relevance
Pls' Trial Ex. 29	PLAINTIFF S001134	2020-2021 Performance Plan for Jeffrey English		X	Objection: Lack of Foundation, Relevance, Hearsay
Pls' Trial Ex. 30	PLAINTIFF S003843	Email communication between Jeffrey English and Devona Pickle – 3/22/22	X		Objection: Lack of Foundation, Relevance, Hearsay, FRE 403
Pls' Trial Ex. 31	PLAINTIFF S001296	AHCA Analysis of Other States' Medicaid Coverage	X		Objection: Authentication,

					Lack of Foundation, Hearsay
Pls' Trial Ex. 32	PLAINTIFF S004219	Miriam Grossman biography	X		Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 33	PLAINTIFF S003821	DSM 5 Gender Dysphoria	X		No Objections
Pls' Trial Ex. 34	PLAINTIFF S006019	WPATH Standards of Care for the Health of Transgender and Gender Diverse People, Version 8	X		Objection: Lack of Foundation, Hearsay, FRE 403
Pls' Trial Ex. 35	PLAINTIFF S005308	WPATH Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, Version 7		X	Objection: Lack of Foundation, Hearsay, FRE 403
Pls' Trial Ex. 36	PLAINTIFF S001203	AACAP Statement Responding to Efforts to Ban Care (Nov. 8, 2019)		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 37	PLAINTIFF S001464	AAFP – Care for Transgender Patients		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 38	PLAINTIFF S001208	AAP – Ensuring Comprehensive Care and Support		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403

Pls' Trial Ex. 39	PLAINTIFF S001222	ACOG Committee Opinion on Health Care for Transgender Individuals (March 2021)		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 40	PLAINTIFF S001278	ACP – Attacks on Gender-Affirming and Transgender Health Care (May 3, 2022)		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 41	PLAINTIFF S001236	LGBT Health Disparities Policy, ACOP		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 42	PLAINTIFF S001456	AMA Letter to Nat'l Gov. Assoc. (April 26, 2021)		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 43	PLAINTIFF S001459	AMA/GLMA Issue Brief on health insurance coverage for gender-affirming care		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 44	PLAINTIFF S001458	AMA Resolution H-185.950		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 45	PLAINTIFF S001466	APA, Guidelines for Psychological Practice with		X	Objection: Lack of Foundation,

		Transgender and Gender Non-conforming People			Authentication, Hearsay, FRE 403
Pls' Trial Ex. 46	PLAINTIFF S001503	APA Resolution on Gender Identity Change Efforts (Feb. 2021)		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 47	PLAINTIFF S001501	APA Position Statement Trans and Gender Diverse Youth (July 2020)		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 48	PLAINTIFF S001499	APA Position Statement on Access to Care (July 2018)		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 49	PLAINTIFF S003880	Endocrine Society Transgender Health Position Statement		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 50	PLAINTIFF S004931	Pediatric Endocrine Society Opposition to Bills that Harm Transgender Youth (April 2021)		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 51	PLAINTIFF S005052	SAHM Statement in Opposition of State Legislation Barring Evidence Based Treatment		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403

Pls' Trial Ex. 52	PLAINTIFF S006014	WMA Statement on Transgender People (Oct. 2015)		X	Objection: Lack of Foundation, Authentication, Hearsay, FRE 403
Pls' Trial Ex. 53	PLAINTIFF S005978	Van Meter Pediatric Endocrinology Excerpt	X		Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 54	PLAINTIFF S004283	Humana Pharmacy Coverage Policy, commercial insurance coverage policy for testosterone – 5/18/2022		X	Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 55	PLAINTIFF S004970	Aetna Clinical Policy Bulletin, coverage of Progestins – 4/27/2023		X	Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 56	PLAINTIFF S003985	Aetna, Clinical Policy Bulletin, gender affirming surgery – 6/22/2023		X	Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 57	PLAINTIFF S004068	Aetna, Clinical Policy Bulletin, GnRHa – 2/23/2023		X	Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 58	PLAINTIFF S004255	Humana, Medical Coverage Policy, cover of gender affirmation surgery – 9/22/2022		X	Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 59	PLAINTIFF S004671	Molina Healthcare, Coverage criteria for Gender		X	Objection: Authentication, Lack of

		Dysphoria Hormone Therapy – July 2023			Foundation, Hearsay
Pls' Trial Ex. 60	PLAINTIFF S004648	Molina Clinical Policy, Gender Affirmation Treatment and Procedures (Marketplace) - 2/8/2023		X	Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 61	PLAINTIFF S005897	UHC Gender Dysphoria Treatment (commercial), 4/1/2023		X	Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 62	PLAINTIFF S001533	Ctrs. for Medicare & Medicaid Servs., EPSDT – A Guide for States: Coverage in the Medicaid Benefit for Children and Adolescents	X		Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 63	PLAINTIFF S001149	Ctrs. for Medicare & Medicaid Servs., CMCS Informational Bulletin (July 21, 2022), https://www.medicaid.gov/federal-policy-guidance/downloads/cib07212022.pdf		X	Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 64	PLAINTIFF S001034	Ctrs. for Medicare & Medicaid Servs., Decision Memo for Gender Dysphoria and Surgery (Aug. 20, 2016)		X	No Objections
Pls' Trial Ex. 65	PLAINTIFF S007539	Office of the Press Secretary, Presidential Memo (Aug. 25, 2017)		X	Objection: Lack of Foundation, Relevance, Hearsay
Pls' Trial Ex. 66	PLAINTIFF S003931	FDA, *Indications and Usage Section of Labeling for Human Prescription*	X		Objection: Lack of Foundation,

		Drug and Biological Products (Draft Guidance) (2018), https://www.fda.gov/files/drugs/published/Indications-and-Usage-Section-of-Labeling-for-Human-Prescription-Drug-and-Biological-Products-%E2%80%94-Content-and-Format-Guidance-for-Industry.pdf			Relevance, Hearsay, FRE 403
Pls' Trial Ex. 67	PLAINTIFF S003951	FDA, *Understanding Unapproved Use of Approved Drugs "Off Label*," (2018), https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label.	X		Objection: Lack of Foundation, Relevance, Hearsay
Pls' Trial Ex. 68	PLAINTIFF S005967	U.S. Drug Enforcement Administration, Drug Scheduling, July 10, 2018, https://www.dea.gov/drug-information/drug-scheduling	X		Objection: Lack of Foundation, Relevance, Hearsay
Pls' Trial Ex. 69	PLAINTIFF S005973	U.S. Comm. on Civil Rights Statement on State Laws Targeting LGBTQ Community, (April 18, 2016)		X	Objection: Lack of Foundation, Relevance, Hearsay
Pls' Trial Ex. 70	PLAINTIFF S001132	U.S. Comm. on Civil Rights Statement on Military Ban (Aug. 18, 2017)		X	Objection: Lack of Foundation, Relevance, Hearsay
Pls' Trial Ex. 71	PLAINTIFF S001006	Dep't of Health & Human Servs., Departmental		X	Objection: Lack of

		Appeals Bd., Appellate Div., Decision No. 2576 (May 30, 2014), hhs.gov/sites/default/files/static/dab/decisions/boarddecisions/2014/dab2576.pdf			Foundation, Relevance, Hearsay
Pls' Trial Ex. 72	PLAINTIFF S004813	OASH, Gender-Affirming Care and Young People		X	No Objections
Pls' Trial Ex. 73	PLAINTIFF S005055	SAMHSA, Ending Conversion Therapy (Oct. 2015)		X	Objection: Lack of Foundation, Relevance, Hearsay
Pls' Trial Ex. 74	PLAINTIFF S005131	SAMHSA, Moving Beyond Change Efforts (2023)		X	Objection: Lack of Foundation, Relevance, Hearsay
Pls' Trial Ex. 75	PLAINTIFF S004794	NCTSN, Gender-Affirming Care is Trauma-Informed Care		X	Objection: Lack of Foundation, Relevance, Hearsay
Pls' Trial Ex. 76	PLAINTIFF S004968	U.S. Presidential Proclamation, Transgender Day of Visibility, 2022		X	Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 77	PLAINTIFF S004966	U.S. Presidential Proclamation, Transgender Day of Visibility, 2023		X	Objection: Lack of Foundation, Relevance
Pls' Trial Ex.78	PLAINTIFF S003887	Executive Order, Preventing and Combating Discrimination on the Basis of Gender Identity or Sexual Orientation (Jan. 20, 2021)	X		Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 79	PLAINTIFF S005990	Medicaid Coverage for Gender-Affirming Care,		X	Objection: Lack of Foundation,

		Williams Institute (Dec. 2022)			Hearsay, FRE 403
Pls' Trial Ex. 80	PLAINTIFF S004432	Excerpts from trial transcript – Vol. 5 (Levine), *Brandt v. Rutledge*, 4:21-CV-00450-JM (E.D. Ark.)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 81	PLAINTIFF S004312	Excerpts from trial transcript – Vol. 6 (Lappert), *Brandt v. Rutledge*, 4:21-CV-00450-JM (E.D. Ark.)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 82	PLAINTIFF S005895	Trial Transcript, *Soneeya v. Turco*, No. 07:12325-DPW (U.S.D.C. Ma.)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 83	PLAINTIFF S001511	Deposition of Stephen Levine, *B.P.J. v. W. VA*, 2:21-CV-00316 (W.D. W.V.)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 84	PLAINTIFF S005841	Transcript of Preliminary Injunction Hearing_Vol. 2, *Eknes-Tucker v. Ivey*, 2:22-cv-00184 (M.D. Ala.)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 85	PLAINTIFF S003214	Deposition of Stephen Levine, *Claire v. D.M.S.*, 4:20-cv-00020 (N.D. Fla.)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 86	PLAINTIFF S003225	Deposition of Stephen Levine, *Fain v. Crouch*, 3:20-cv-00740 (S.D. W. Va.)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 87	PLAINTIFF S003280	Deposition of Stephen Levine, *Kadel v. Folwell*, 1:19-cv-272 (M.D. N.C.)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 88	PLAINTIFF S003153	Deposition of Kim G. Hutton, *Adams v. St. Johns*, No. 3:17-cv-00739 (M.D. Fla.)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 89	PLAINTIFF S003890	Expert Declaration of Paul W. Hruz, *Adams v. St. Johns*, No. 3:17-cv-00739 (M.D. Fla.)		X	Objection: Hearsay, Relevance

Pls' Trial Ex. 90	PLAINTIFF S002980	Deposition of Paul W. Hruz, *Adams v. St. Johns*, No. 3:17-cv-00739 (M.D. Fla.)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 91	PLAINTIFF S003032	Deposition of Paul W. Hruz, Bruce v. South Dakota, No. 17-5080 (USDC SD)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 92	PLAINTIFF S002158	Declaration of Norman P. Spack, *Adams v. St. Johns*, No. 3:17-cv-00739 (M.D. Fla.)		X	Objection: Hearsay, Relevance
Pls' Trial Ex. 93	PLAINTIFF S002162	Expert Declaration of Paul W. Hruz, *Whitaker v. Kenos*ha, 2:16-cv-00943 (E.D. Wis.)		X	Objection: Hearsay, Relevance
Pls' Trial Ex. 94	PLAINTIFF S003042	Deposition of Paul W. Hruz, *Kadel v. Folwell*, 1:19-cv-00272 (M.D. N.C.)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 95	PLAINTIFF S001582;	Deposition of Patrick Lappert, *Kadel v. Folwell*, 1:19-cv-00272 (M.D. N.C.)		X	Objection: Hearsay, Relevance
Pls' Trial Ex. 96	PLAINTIFF S003168	Deposition of Michael Laidlaw, *C.P. v. Blue Cross*, 3:20-cv-066145 (W.D. Wa.)	X		Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 97	PLAINTIFF S003323	Deposition of Van Meter, *Grimm v. Gloucester County School Bd.* (3/18/2019)	X		Objection: Hearsay, Relevance
Pls' Trial Ex. 98	PLAINTIFF S004235	Hearing on Motion for Temporary Injunction, *PFLAG v. Abbott*, No. D-1-GN-22-002569 (Tex. Dist. Ct., Travis Cnty.)		X	Objection: FRE 106, Hearsay, Relevance
Pls' Trial Ex. 99	PLAINTIFF S003841	Email communication between Gonzalez-Pagan and Lisa Tetrault (4/4/2023)		X	Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 100	PLAINTIFF S005301	Shupe email (3/30/2020)	X		Objection: Authentication,

					Lack of Foundation, Hearsay, Relevance, FRE 610, FRE 403
Pls' Trial Ex. 101	PLAINTIFF S001526	Clark email (3/19/2020)	X		Objection: Authentication, Lack of Foundation, Hearsay, Relevance, FRE 403
Pls' Trial Ex. 102	PLAINTIFF S001521	Broyles email (10/30/2019)	X		Objection: Authentication, Lack of Foundation, Hearsay, Relevance, FRE 610, FRE 403
Pls' Trial Ex. 103	PLAINTIFF S005975	Van Meter email (2/4/2020)	X		Objection: Authentication, Lack of Foundation, Hearsay, Relevance, FRE 403
Pls' Trial Ex. 104	PLAINTIFF S007478	*A Texas judge ruled this doctor was not an expert*, Pennsylvania Capital-Star (Sept. 15, 2020)	X		Objection: Hearsay, Relevance
Pls' Trial Ex. 105	PLAINTIFF S003965;	*First, do no harm: thinking through transgender issues*, Zanga (Aug. 1, 2018)	X		Objection: Hearsay
Pls' Trial Ex. 106	PLAINTIFF S003968	*First, do no harm*, Zanga, AHCA Production	X		Objection: Hearsay

Pls' Trial Ex. 107	PLAINTIFF S005436	The Bulletin, Vol. 63, No. 6 (June 2018) – *First, do no harm*	X		Objection: Hearsay
Pls' Trial Ex. 108	PLAINTIFF S004799	*Neurobiology of gender identity and sexual orientation*, 2018 Roselli	X		Objection: Hearsay, Lack of Foundation
Pls' Trial Ex. 109	PLAINTIFF S001577	Correction to Littman (March 19, 2019)		X	Objection: Hearsay, Lack of Foundation
Pls' Trial Ex. 110	PLAINTIFF S001574	Comment on Littman, Costa 2019	X		Objection: Hearsay, Lack of Foundation
Pls' Trial Ex. 111	PLAINTIFF S005026	*Psychotherapy for Unwanted Homosexual Attraction*, ACOP (Jan 2016)	X		Objection: Hearsay, Lack of Foundation
Pls' Trial Ex. 112	PLAINTIFF S004250	*Homosexual Parenting*, ACOP (May 2019)	X		Objection: Hearsay, Lack of Foundation, FRE 403
Pls' Trial Ex. 113	PLAINTIFF S004029	*Gender Dysphoria in Children*, ACOP (Nov. 2018)	X		Objection: Hearsay, Lack of Foundation, FRE 403
Pls' Trial Ex. 114	PLAINTIFF S005986	*Why We Stand Up for Transgender Children and Teens*, AAP (Aug. 10, 2022)	X		Objection: Hearsay, Lack of Foundation, FRE 403
Pls' Trial Ex. 115	PLAINTIFF S001205	*AAP continues to support care of transgender youths*, AAP (Jan. 6, 2022)	X		Objection: Hearsay, Lack of Foundation, FRE 403
Pls' Trial Ex. 116	PLAINTIFF S003924	*Facts, not flattery, about same-sex attraction*, MERCATOR (May 22, 2007)	X		Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 117	PLAINTIFF S004932	*Pediatricians' Groups Differ On Attitudes Toward*	X		Objection: Authentication,

		Homosexual Parenting, Waller and Nicolosi (July 17, 2003)			Lack of Foundation, Hearsay
Pls' Trial Ex. 118	PLAINTIFF S003838	*Elect Candidates Who Support the Best for Children*, ACOP (Oct. 2018)	X		Objection: Authentication, Lack of Foundation, Hearsay, FRE 403
Pls' Trial Ex. 119	PLAINTIFF S004291	*International clinical practice guidelines for gender minority/trans people*, 2021 Dahlen et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 120	PLAINTIFF S005832	The Journal of the Amer. Acad. Of Psychiatry and the Law	X		Objection: Lack of Foundation, Hearsay, FRE 403
Pls' Trial Ex. 121	PLAINTIFF S004815	*On Gender Dysphoria*, 2017 Dhejne		X	Objection: Lack of Foundation, Hearsay, FRE 106
Pls' Trial Ex. 122	PLAINTIFF S004629	*Long-Term Follow-up of Transsexual Persons Undergoing Sex Reassignment Surgery*, 2011 Dhejne		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 123	PLAINTIFF S003882	*Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons*, 2017 Hembree et al.		X	Objection: Lack of Foundation, Hearsay, FRE 403
Pls' Trial Ex. 124	PLAINTIFF S004302	*Interrogating Gender-Exploratory Therapy*, 2023 Ashley		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 125	PLAINTIFF S004819	*Transgender Surgery & Christian Anthropology*,		X	Objection: Lack of

		Presentation by Patrick W. Lappert			Foundation, Hearsay, FRE 610
Pls' Trial Ex. 126	PLAINTIFF S005980	*What is Psychiatry*, American Psychiatric Association		X	Objection: Lack of Foundation, Hearsay, FRE 403
Pls' Trial Ex. 127	PLAINTIFF S004222	Lewis's Child and Adolescent Psychiatry, Fifth Edition, 2018		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 128	PLAINTIFF S003970	*Memo Outlining Evidence for Change for Gender Identity Disorder in the DSM-5*, 2013 Zucker, et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 129	PLAINTIFF S001173	*A Developmental, Biopsychosocial Model for the Treatment of Children with Gender Identity Disorder*, 2012 Zucker	X		Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 130	PLAINTIFF S001510	APA Statement on Zucker (2008)	X		Objection: Authentication, Lack of Foundation, Hearsay, FRE 403
Pls' Trial Ex. 131	PLAINTIFF S004475	Working for Inclusion: Time for Congress to Enact Federal Legislation to Address Workplace Discrimination Against Lesbian, Gay, Bisexual, and Transgender Americans, Briefing Report		X	Objection: Lack of Foundation, Hearsay, Relevance
Pls' Trial Ex. 132	PLAINTIFF S004963	Position Statement on Conversion Therapy, APA (Dec. 2018)	X		Objection: Lack of Foundation, Hearsay,

					Relevance, FRE 403
Pls' Trial Ex. 133	PLAINTIFF S005046	*Do Clinical Data from Transgender Adolescents Support the Phenomenon of Rapid Onset Gender Dysphoria*, 2022 Bauer et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 134	PLAINTIFF S003921	American Society of Plastic Surgeons, *State Focus on Gender Affirmation Intensifies*, Feb. 25, 2021, https://www.plasticsurgery.org/for-medical-professionals/advocacy/advocacy-news/state-focus-on-gender-affirmation-intensifies.		X	Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 135	PLAINTIFF S004934	*Plastic surgeon: Sex-change operation 'utterly unacceptable' and a form of 'child abuse,'* Sept. 9, 2019, https://www.lifesitenews.com/news/plastic-surgeon-sex-change-operation-utterly-unacceptable-and-a-form-of-child-abuse/.		X	Objection: Authentication, Lack of Foundation, Hearsay, FRE 610
Pls' Trial Ex. 136	PLAINTIFF S005870	*Transphobic tweets linked to Oxford sociology professor*, The Oxford Student (Oct. 26, 2018)		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 137	PLAINTIFF S004637	*Long-term outcomes of the treatment of central precocious puberty*, 2016 Guaraldi, et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 138	PLAINTIFF S003955	*Fertility of Women Treated during Childhood with Triptorelin (Depot*		X	Objection: Lack of

		Formulation) for Central Precocious Puberty, 2021 Martinerie, et al.			Foundation, Hearsay
Pls' Trial Ex. 139	PLAINTIFF S004021	*Gender dysphoria in childhood*, 2016 Ristori & Steensman		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 140	PLAINTIFF S004049;	*Gender Identity 5 Years After Social Transition*, 2022 Olson et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 141	PLAINTIFF S006594	*Puberty Suppression in Adolescents With Gender Identity Disorder*, 2011 de Vries, et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 142	PLAINTIFF S005914	*Understanding the Well-Being of LGBTQI+ Populations*, 2020 Nat'l Academies of Sciences, Engineering, and Medicine		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 143	PLAINTIFF S005465	*The Health of Lesbian, Gay, Bisexual and Transgender People*, 2011 Nat'l Academies of Sciences, Engineering, and Medicine		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 144	PLAINTIFF S005837	*The Right to the Best Care for Children Does Not Include the Right to Medical Transition*, 2019 Laidlaw, et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 145	PLAINTIFF S005428	*Strangers in a Strange Land*, 2020 Donovan & Sotomayor		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 146	PLAINTIFF S003830	*Effect of antidepressant medications on semen parameters and male fertility*, 2020 Beeder & Samplaski		X	Objection: Lack of Foundation, Hearsay

Pls' Trial Ex. 147	PLAINTIFF S005460	*The effect of antidepressants on fertility*, 2016 Casilla-Lennon, et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 148	PLAINTIFF S005888	*Trends in Gender-affirming Surgery in Insured Patients in the U.S.*, 2018 Lane et al.		X	Objection: Lack of Foundation, Hearsay
		UCSF Ctr. For Excellence in Transgender Care Guidelines, https://transcare.ucsf.edu/guidelines (online only)	X		Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 149	PLAINTIFF S004056	*Gender-Affirming Treatment of Gender Dysphoria in Youth*, 2022 Clayton et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 150	PLAINTIFF S006279	AAP News, *Risk of Pseudotumor Cerebri added to Labeling for Gonadotropin-Releasing Hormone Agonists*, (2022)		X	Objection: Lack of Foundation, Hearsay, FRE 403
Pls' Trial Ex. 151	PLAINTIFF S006281	*Longitudinal Impact of Gender-Affirming Endocrine Intervention on the Mental Health and Well-Being of Transgender Youths*, 2020 Achille et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 152	PLAINTIFF S006286	*Long-Term Effect of Gender-Affirming Hormone Treatment on Depression and Anxiety Symptoms in Transgender People,* 2020 Aldridge et al.		X	Objection: Lack of Foundation, Hearsay

Pls' Trial Ex. 153	PLAINTIFF S006295	*Off-Label Medication use in Children, More Common than We Think: A Systematic Review of the Literature,* 2018 Allen et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 154	PLAINTIFF S006314	*Association Between Gender-Affirming Surgeries and Mental Health Outcomes*, 2021 Almazan et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 155	PLAINTIFF S006322	*Top Surgery and Chest Dysphoria Among Transmasculine and Nonbinary Adolescents and Young Adults*, 2022 Ascha et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 156	PLAINTIFF S006330	*Hormone Therapy, Mental Health, and Quality of Life Among Transgender People: A Systematic Review*, 2021 Baker et al.		X	Objection: Lack of Foundation, Hearsay, FRE 403
Pls' Trial Ex. 157	PLAINTIFF S006346	*GRADE Guidelines: 3 Rating the Quality of Evidence,* 2011 Balshem et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 158	PLAINTIFF S006352	Harry Benjamin, *The Transsexual Phenomenon* (1966)		X	Objection: Authentication, Lack of Foundation, Hearsay
Pls' Trial Ex. 159	PLAINTIFF S006492	*Anabolic Steroid Abuse and Dependence*, 2002 Brower et al.		X	Objection: Lack of Foundation, Hearsay

Pls' Trial Ex. 160	PLAINTIFF S006516	*Transgender and Gender-Nonbinary Patient Satisfaction after Transmasculine Chest Surgery*, 2021 Bustos et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 161	PLAINTIFF S006503	*Regret after Gender-affirmation Surgery: A Systematic Review and Metaanalysis of Prevalence*, 2021 Bustos et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 162	PLAINTIFF S006526	*Effects of Long-Term Exogenous Testosterone Administration on Ovarian Morphology, Determined by Transvaginal (3D) Ultrasound in Female-to-Male Transsexuals*, 2017 Caanen et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 163	PLAINTIFF S006534	*Short-term Outcomes of Pubertal Suppression in a Selected Cohort of 12 to 15 Year Old Young People with Persistent Gender Dysphoria in the UK*, 2021 Carmichael at al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 164	PLAINTIFF S006560	*Psychosocial Functioning in Transgender Youth after 2 Years of Hormones*, 2023 Chen et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 165	PLAINTIFF S006571	*Pubertal Delay as an Aid in Diagnosis and Treatment of a Transsexual Adolescent*, 1998 Cohen-Kettenis & van Goozen		X	Objection: Lack of Foundation, Hearsay

Pls' Trial Ex. 166	PLAINTIFF S006574	*Hormonal Treatment Reduces Psychobiological Distress in Gender Identity Disorder, Independently of the Attachment Style*, 2013 Colizzi et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 167	PLAINTIFF S006585	*Psychological Support, Puberty Suppression, and Psychosocial Functioning in Adolescents with Gender Dysphoria*, 2015 Costa et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 168	PLAINTIFF S006602	*Young Adult Psychological Outcome After Puberty Suppression and Gender Reassignment*, 2014 de Vries et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 169	PLAINTIFF S006611	*An Analysis of All Applications for Sex Reassignment Surgery in Sweden, 1960-2010: Prevalence, Incidence, and Regrets*, 2014 Dhejne et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 170	PLAINTIFF S006623	*Gender Nonconforming Youth: Current Perspectives*, 2017 Ehrensaft		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 171	PLAINTIFF S006634	*What makes clinical research ethical?,* 2000 Emanuel et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 172	PLAINTIFF S006645	*Treatment of Central Precocious Puberty*, 2019 Eugster		X	Objection: Lack of Foundation, Hearsay

Pls' Trial Ex. 173	PLAINTIFF S006653	*Cross-Sex Hormone Treatment and Psychobiological Changes in Transsexual Persons: Two-Year Follow-Up Data*, 2016 Fisher et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 174	PLAINTIFF S006663	*Chest Surgery in Female to Male Transgender Individuals*, 2017 Frederick et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 175	PLAINTIFF S006668	*Off-Label Use of Drugs in Children,* 2014 Galinkin et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 176	PLAINTIFF S006676	*Association of Gender-Affirming Hormone Therapy With Depression, Thoughts of Suicide, and Attempted Suicide Among Transgender and Nonbinary Youth*, 2022 Green		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 177	PLAINTIFF S006693	*Feminizing Genital Gender-Confirmation Surgery*, 2018 Hadj-Moussa et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 178	PLAINTIFF S006707	*Satisfaction with Male-to-Female Gender Reassignment Surgery*, 2014 Hess et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 179	PLAINTIFF S006717	*Effects of Different Steps in Gender Reassignment Therapy on Psychopathology*, 2014 Heylens, et al.		X	Objection: Lack of Foundation, Hearsay

Pls' Trial Ex. 180	PLAINTIFF S006725	*Supporting Sexuality and Improving Sexual Function in Transgender Persons*, 2019 Holmberg et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 181	PLAINTIFF S006744	*Outcome of Vaginoplasty in Male-to-Female Transgenders: A Systematic Review of Surgical Techniques*, 2015 Horbach et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 182	PLAINTIFF S006759	*The Quality of Evidence for Medical Interventions Does Not Improve or Worsen: A Metaepidemiological Study of Cochrane Reviews*, 2020 Howick et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 183	PLAINTIFF S006765	*Testosterone Treatment and MMPI–2 Improvement in Transgender Men*, 2015 Keo-Meier et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 184	PLAINTIFF S006779	*Bone Mass in Young Adulthood Following Gonadotropin-Releasing Hormone Analog Treatment and Cross-Sex Hormone Treatment in Adolescents with Gender Dysphoria*, 2015 Klink et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 185	PLAINTIFF S006785	*Fertility Options in Transgender and Gender Diverse Adolescents*, 2017 Knudson & De Sutter		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 186	PLAINTIFF S006789	*Australian Children and Adolescents with Gender*		X	Objection: Lack of

		Dysphoria, 2021 Kozlowska et al.			Foundation, Hearsay
Pls' Trial Ex. 187	PLAINTIFF S006815	*Body Dissatisfaction and Mental Health Outcomes of Youth on Gender-Affirming Hormone Therapy*, 2020 Kuper et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 188	PLAINTIFF S006824	*Transgender Men Who Experienced Pregnancy After Female-to-Male Gender Transitioning*, 2014 Light, et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 189	PLAINTIFF S006833	*Psychosocial Assessment in Transgender Adolescents*, 2020 Lopez de Lara.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 190	PLAINTIFF S006841	Christy Mallory et al., *Conversion Therapy and LGBT Youth* 2 (2019 ed.)		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 191	PLAINTIFF S006852	*Successful Oocyte Cryopreservation Using Letrozole as an Adjunct to Stimulation in a Transgender Adolescent after GnRH Agonist Suppression*, 2021 Martin et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 192	PLAINTIFF S006858	*Experience of Chest Dysphoria and Masculinizing Chest Surgery in Transmasculine Youth*, 2021 Mehringer et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 193	PLAINTIFF S006867	*Breast Augmentation in Male-to-Female Transgender Patients:*		X	Objection: Lack of

		Technical Considerations and Outcomes, 2019 Miller et al.			Foundation, Hearsay
Pls' Trial Ex. 194	PLAINTIFF S006879	*Guiding the Conversation—Types of Regret after Gender-Affirming Surgery and Their Associated Etiologies*, 2021 Narayan et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 195	PLAINTIFF S006891	*Individual Treatment Progress Predicts Satisfaction with Transition-Related Care for Youth with Gender Dysphoria*, 2021 Nieder et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 196	PLAINTIFF S006905	*Sexual Experiences in Transgender People*, 2018 Nikkelen & Baudewijntje.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 197	PLAINTIFF S006918	*Quality of Life of Treatment-Seeking Transgender Adults*, 2018 Nobili et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 198	PLAINTIFF S006955	*Chest Reconstruction and Chest Dysphoria in Transmasculine Minors and Young Adults: Comparisons of Nonsurgical and Postsurgical Cohorts*, 2018 Olson-Kennedy et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 199	PLAINTIFF S006940	*Mental Health of Transgender Children Who Are Supported in Their Identities*, 2016 Olson, et al.		X	Objection: Lack of Foundation, Hearsay

Pls' Trial Ex. 200	PLAINTIFF S006961	*Association Between Gender Confirmation Treatments and Perceived Gender Congruence, Body Image Satisfaction, and Mental Health in a Cohort of Transgender Individuals*, 2018 Owen-Smith, et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 201	PLAINTIFF S006981	*Male-to-Female Sex Reassignment Surgery Using the Combined Technique Leads to Increased Quality of Life in a Prospective Study*, 2017 Papadopulos et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 202	PLAINTIFF S006990	*Sex Reassignment. Thirty Years of International Follow-up Studies After Sex Reassignment Surgery: A Comprehensive Review, 1961-1991*, 1998 Pfafflin & Junge		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 203	PLAINTIFF S006997	*Advancing Methods for U.S. Transgender Health Research*, 2015 Reisner		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 204	PLAINTIFF S007008	*Approach to the Patient: Transgender Youth: Endocrine Considerations*, 2014 Rosenthal		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 205	PLAINTIFF S007019	*Oocyte Cryopreservation in a Transgender Male Adolescent*, 2019 Rothenberg et al.		X	Objection: Lack of Foundation, Hearsay

Pls' Trial Ex. 206	PLAINTIFF S007021	Royal College of Psychiatrists, *Good Practice Guidelines for the Assessment and Treatment of Adults with Gender Dysphoria* (2013).		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 207	PLAINTIFF S007083	*Transgender Associations and Possible Etiology:A Literature Review*, 2017 Saleem & Rizvi		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 208	PLAINTIFF S007088	*Regret Associated with the Decision for Breast Reconstruction*, 2008 Sheehan et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 209	PLAINTIFF S007103	*Sex Reassignment: Outcomes and Predictors of Treatment for Adolescent and Adult Transsexuals*, 2005 Smith, et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 210	PLAINTIFF S007114	*Gender-Affirming Mastectomy Trends and Surgical Outcomes in Adolescents*, 2022 Tang et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 211	PLAINTIFF S007121	*Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care*, 2022 Tordoff et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 212	PLAINTIFF S007134	*Endocrinology of Transgender Medicine*, 2018 Guy T'Sjoen et al.		X	Objection: Lack of Foundation, Hearsay

Pls' Trial Ex. 213	PLAINTIFF S007155	*Alterations in Body Uneasiness, Eating Attitudes, and Psychopathology Before and After Cross-Sex Hormonal Treatment in Patients with Female-to-Male Gender Dysphoria*, 2018 Turan et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 214	PLAINTIFF S007169	*Association Between Recalled Exposure to Gender Identity Conversion Efforts and Psychological Distress and Suicide Attempts Among Transgender Adults*, 2020 Turban et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 215	PLAINTIFF S007186	*Access to Gender-Affirming Hormones during Adolescence and Mental Health Outcomes Among Transgender Adults*, 2022 Turban et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 216	PLAINTIFF S007178	*Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation*, 2020 Turban et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 217	PLAINTIFF S007201	*Surgical Satisfaction, Quality of Life, and Their Association After Gender-Affirming Surgery: A Follow-up Study*, 2018 van de Grift et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 218	PLAINTIFF S007213	*Psychological Functioning in Transgender Adolescents*		X	Objection: Lack of

		Before and After Gender-Affirmative Care Compared With Cisgender General Population Peers, 2020 R. van der Miesen			Foundation, Hearsay
Pls' Trial Ex. 219	PLAINTIFF S007220	*Effect of Pubertal Suppression and Cross-Sex Hormone Therapy on Bone Turnover Markers and Bone Mineral Apparent Density (BMAD) in Transgender Adolescents, in Bone in Balance* 2020 Vlot		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 220	PLAINTIFF S007419	*Patient Satisfaction with Breasts and Psychosocial, Sexual, and Physical Well-Being after Breast Augmentation in Male-to-Female Transsexuals*, 2013 Weigert et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 221	PLAINTIFF S007428	*Cross-Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short-Time Follow-Up*, 2014 Wierckx et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 222	PLAINTIFF S007441	*Ten Common Questions (and Their Answers) About Off-label Drug Use*, 2012 Wittich et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 223	PLAINTIFF S007450	*Cognitive, Emotional, and Psychosocial Functioning of Girls Treated with Pharmacological Puberty Blockage for Idiopathic*		X	Objection: Lack of Foundation, Hearsay

		Central Precocious Puberty, 2016 Wojniusz et al.			
Pls' Trial Ex. 224	PLAINTIFF S007462	*Off-label Medication Prescribing Patterns in Pediatrics: An Update*, 2019 Yackey et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 225	PLAINTIFF S007470	*Functional Ovarian Reserve in Transgender Men Receiving Testosterone Therapy*, 2021 Yaish et al.		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 226	PLAINTIFF S006683	*Management of Endocrine Disease: Long term outcome of central precocious puberty*		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 227	PLAINTIFF S001128	Presidential Memorandum for the Secretary of Defense and the Secretary of Homeland Security Regarding Military Service by Transgender Individuals (March 23, 2018)		X	Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 228	Intentionally Left Blank				
Pls' Trial Ex. 229	PLAINTIFF S001343	Template Notice of Adverse Benefit Determination	X		No Objections
Pls' Trial Ex. 230	PLAINTIFF S001294	Template Notice of Plan Appeal Resolution	X		No Objections
Pls' Trial Ex. 231	PLAINTIFF S001286	Sample AHCA Final Order – 20-FH0855		X	No Objections
Pls' Trial Ex. 232	PLAINTIFF S000818 - PLAINTIFF S000838	Medical records of August Dekker	X		No Objections
Pls' Trial Ex. 233	Intentionally Left Blank				

Pls' Trial Ex. 234	PLAINTIFF S000168 thru PLAINTIFF S000182	Medical records of Brit Rothstein	X		No Objections
Pls' Trial Ex. 234A	PLAINTIFF S000839 thru PLAINTIFF S000998	Medical records of Brit Rothstein	X		No Objections
Pls' Trial Ex. 235	PLAINTIFF S000041 thru PLAINTIFF S000167	Medical records of K.F.	X		No Objections
Pls' Trial Ex. 235A	PLAINTIFF S000200 thru PLAINTIFF S000647	Medical records of K.F.	X		No Objections
Pls' Trial Ex. 236	PLAINTIFF S000001 thru PLAINTIFF S000040	Medical records of S.D.	X		No Objections
Pls' Trial Ex. 236A	PLAINTIFF S000183 thru PLAINTIFF S000199	Medical records of S.D.	X		No Objections
Pls' Trial Ex. 236B	PLAINTIFF S000648 thru PLAINTIFF S000817	Medical records of S.D.	X		No Objections

Pls' Trial Ex. 236C	PLAINTIFF S000999 thru PLAINTIFF S001005	Medical records of S.D.	X		No Objections
Pls' Trial Ex. 237	Def_001562 290	Dekker medical records	X		No Objections
Pls' Trial Ex. 237A	Def_001557 555	Dekker medical records	X		No Objections
Pls' Trial Ex. 238	Def_000174 290	GAPMS Decision Tree Checklist	X		No Objections
Pls' Trial Ex. 239	Def_000286 939	GAPMS – GnRH for treatment of gender dysphoria	X		No Objections
Pls' Trial Ex. 240	Def_000288 776	GAPMS – GnRH for treatment of gender dysphoria	X		No Objections
Pls' Trial Ex. 241	Def_000126 105	GAPMS – Cross Sex Hormone Therapy – 5/20/2022	X		No Objections
Pls' Trial Ex. 242	Def_000086 666	GAPMS – Cross Sex Hormone Therapy Report (edited) - 5/20/2022	X		No Objections
Pls' Trial Ex. 243	Def_000293 866	GAPMS – Cross Sex Hormone Therapy – 11/2/2016	X		No Objections
Pls' Trial Ex. 244	Def_000295 586	GAPMS – Gender Confirmation Surgery (incomplete) – 7/19/2017		X	No Objections
Pls' Trial Ex. 245	Def_000322 520	DUR Meeting Transcript – 9/26/2015		X	Objection: Relevance
Pls' Trial Ex. 246	Def_000320 588	DUR Quarterly Report - 2015		X	Objection: Relevance
Pls' Trial Ex. 247	Def_000331 626	DUR Meeting Minutes – 1/16/2016		X	Objection: Relevance
Pls' Trial Ex. 248	Def_000364 680	DUR Meeting Minutes – 9/24/2016		X	Objection: Relevance
Pls' Trial Ex. 249	Def_000344 341	Pharmacy log – 5/31/2016		X	Objection: Relevance

Pls' Trial Ex. 250	Def_000351 681	AHCA review of research – 7/25/2016		X	No Objections
Pls' Trial Ex. 251	Def_000356 616	AHCA review of state practice – 8/17/2016		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 252	Def_000352 792	Arlene Elliot research regarding Medicaid coverage of care in other states – July 27, 2016	X		Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 252A	Def_000352 793	Arlene Elliot research regarding Medicaid coverage of care in other states – July 27, 2016	X		Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 252B	Def_000355 079	Arlene Elliot research regarding Medicaid coverage of care in other states – July 27, 2016	X		Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 252C	Def_000355 079-1	Arlene Elliot research regarding Medicaid coverage of care in other states – July 27, 2016	X		Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 253	Def_000360 646	Aetna clinical criteria for cross-sex hormone therapy – 8/18/2016		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 254	Def_000369 549	Arlene Elliot email re GnRH coverage – 8/29/2016	X		Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 255	Def_000366 785	Rebecca Borgert email regarding Endocrine Society guidelines – 8/29/2016	X		Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 256	Def_000289 927	AHCA GAPMS routing and tracking form for puberty suppression therapy – 8/31/2016	X		No Objections

Pls' Trial Ex. 257	Def_000148 820	Special services criteria re GnRH coverage – 9/20/2016 (updated 11/17/17)	X		No Objections
Pls' Trial Ex. 258	Def_000363 625	AHCA letter to Children's Medical Services re drug criteria and coverage – 10/6/2016		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 259	Def_000368 873	AHCA tracking form for GAPMS research re puberty suppression – 9/26/2016		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 260	Def_000295 599	AHCA GAPMS routing and tracking form for cross-sex hormone therapy – 11/2/2016	X		No Objections
Pls' Trial Ex. 261	Def_000374 025	FL House letter to AHCA re drug treatment for gender dysphoria – 11/22/2016		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 262	Def_000434 874	DUR transcript – 3/23/2017	X		Objection: Relevance
Pls' Trial Ex. 263	Def_000289 947	Draft GAPMS re gender-affirming surgery – 7/19/2017	X		Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 264	Def_000824 992	Email exchange re Medicaid coverage of gender affirming surgery – June 2018	X		No Objections
Pls' Trial Ex. 264A	Def_000824 996	Email exchange re Medicaid coverage of gender affirming surgery – June 2018	X		No Objections
Pls' Trial Ex. 265	Def_000825 001	AHCA routing form tracking response to MCO question about Medicaid coverage of surgery – June 2018	X		No Objections

Pls' Trial Ex. 266	Def_000825 002	AHCA document closing the project re responding to MCO question about Medicaid coverage of surgery – June 2018	X		No Objections
Pls' Trial Ex. 267	Def_001291 353	Email from Theresa Kumar to Jesse Botcher – 10/18/2019	X		Objection: Relevance
Pls' Trial Ex. 268	Def_001463 652	Email from DD Pickle to Krisin Sokoloski – 1/5/2022		X	Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 269	Def_000075 977	AHCA approval of Simply Healthcare's provider manual – 3/24/2022	X		Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 269A	Def_000075 979	AHCA approval of Simply Healthcare's provider manual – 3/24/2022	X		Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 269B	Def_000023 694	AHCA approval of Simply Healthcare's provider manual – 3/24/2022	X		Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 269C	Def_000055 220	AHCA approval of Simply Healthcare's provider manual – 3/24/2022	X		Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 270	Def_000076 888	Email re commercial plan coverage – 3/24/2022	X		Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 271	Def_001490 062	Communication from Peter Ring re procedures billed to treat gender dysphoria – 4/7/2022	X		Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 272	Def_000290 175	Email from Andy Bardos to Andrew Sheeran re Cantor	X		No Objections

Pls' Trial Ex. 284	Def_002174 114	Jason Weida communication regarding articles provided to him by Dr. Van Mol – 5/6/2022	X		No Objections
Pls' Trial Ex. 285	Def_001497 585	Dr. Van Mol communication with Jason Weida and Matthew Brackett about gender affirming care – 5/7/022	X		No Objections
Pls' Trial Ex. 286	Def_000296 902	Dr. Van Mol's edits to June 2022 GAPMS memo – 5/13/2022	X		No Objections
Pls' Trial Ex. 286A	Def_000296 902-1	Dr. Van Mol's edits to June 2022 GAPMS memo – 5/13/2022	X		No Objections
Pls' Trial Ex. 286B	Def_000296 902-2	Dr. Van Mol's edits to June 2022 GAPMS memo – 5/13/2022	X		No Objections
Pls' Trial Ex. 287	EOG_00812 6	Text message from Jason Weida regarding Eknes-Tucker and James Cantor – 5/17/2022	X		No Objections
Pls' Trial Ex. 288	Def_001968 264	Email from Shantrice Green to Susan Williams and Kelly Rubin regarding the GAPMS memo on cross-sex hormone therapy – 5/20/2022	X		No Objections
Pls' Trial Ex. 289	Def_002878 820	Draft of GAPMS cross-sex hormone therapy memo – 5/20/2022	X		No Objections
Pls' Trial Ex. 290	AHCA EXP_00476 2	Jason Weida asks Dr. Van Mol for assistance locating specific witnesses – 5/21/2022	X		Objection: Relevance

Pls' Trial Ex. 291	Def_000291698	Email between Dr. Van Mol and Jason Weida regarding reimbursement – 5/21/2022	X		Objection: Relevance
Pls' Trial Ex. 292	Def_002885062	Invoices from Romina Brignardello-Petersen – 5/24/2022	X		Objection: Relevance
Pls' Trial Ex. 292A	Def_002885063	Invoices from Romina Brignardello-Petersen – 5/24/2022	X		Objection: Relevance
Pls' Trial Ex. 293	Def_000286991	Template denial for requesting rule workshop – June 2022		X	Objection: Lack of Foundation, Relevance
Pls' Trial Ex. 294	EOG_008239	Projected Rulemaking Timeline – June 2022	X		No Objections
Pls' Trial Ex. 295	EOG_008240	Gender Dysphoria/Transgender Health Care Non-Legislative Pathway – June 2022	X		Objection: Lack of Foundation
Pls' Trial Ex. 296	EOG_008241	Gender Dysphoria/Transgender Health Care Policy Pathway – June 2022	X		Objection: Lack of Foundation
Pls' Trial Ex. 297	Def_000295608	AHCA GAPMS routing and tracking form for June 2022 GAPMS – 6/1/2022	X		No Objections
Pls' Trial Ex. 297A	Def_000288171	AHCA GAPMS routing and tracking form for June 2022 GAPMS – 6/1/2022	X		No Objections
Pls' Trial Ex. 298	Def_002873411	Communication between Ashley Peterson and Jason Weida regarding an inventory of gender affirming care – 6/3/2022		X	No Objections
Pls' Trial Ex. 298A	Def_002873412	Communication between Ashley Peterson and Jason		X	No Objections

		Weida regarding an inventory of gender affirming care – 6/3/2022			
Pls' Trial Ex. 299	Def_000288 753	Email communication between AHCA and Magellan regarding coverage of GnRH to treat gender dysphoria	X		No Objections
Pls' Trial Ex. 300	Def_001900 110	AHCA communication regarding the Special Services Criteria for puberty blockers – 6/10/2022	X		No Objections
Pls' Trial Ex. 301	Def_001900 113	Communication between Jason Weida and Dr. Van Mol about a witness for the July 8th hearing – 6/14/2022	X		No Objections
Pls' Trial Ex. 302	Def_000174 299	Email communication between Dr. Christopher Cogle and Jeffrey English – 6/27/2022	X		Objection: Hearsay
Pls' Trial Ex. 303	GROSSMA N0095	Communication regarding meeting between Miriam Grossman, Dr. Van Mol, Jason Weida, Andrew Sheeran, and Holtzman Vogel regarding July 8th hearing – 6/30/2022	X		No Objections
Pls' Trial Ex. 304	Def_000296 975	Communication between Dr. Van Mol and AHCA - 7/2/2022	X		No Objections
Pls' Trial Ex. 305	FDOH_0000 04873	Brief of the July 8th rule hearing – 7/8/2022	X		No Objections
Pls' Trial Ex. 306	Def_000296 244	Transcript from July 8th rule hearing – 7/8/2022	X		No Objections
Pls' Trial Ex. 307	Def_000296 949	Email from Miriam Grossman – 7/10/2022	X		No Objections

Pls' Trial Ex. 308	Def_000291900	Email communications with Jason Weida and Dr. Van Mol – 7/14/2022	X		No Objections
Pls' Trial Ex. 309	GROSSMAN0067	Communications regarding AHCA's development of public comment binder provided to the consultants – 7/19/2022	X		No Objections
Pls' Trial Ex. 310	Def_000237607	Invoice from Dr. Van Meter – 8/4/2022	X		No Objections
Pls' Trial Ex. 311	EOG_008127	Communication to Jason Weida regarding witnesses for a hearing – 8/10/2022	X		No Objections
Pls' Trial Ex. 312	Def_000239820	Invoices from Dr. Van Mol – 8/11/2022	X		No Objections
Pls' Trial Ex. 313	Def_001892888	Email communications regarding implementation of 59G-1.050(7) - 8/22/2022		X	Objection: Relevance
Pls' Trial Ex. 313A	Def_001892894	Email communications regarding implementation of 59G-1.050(7) - 8/22/2022		X	Objection: Relevance
Pls' Trial Ex. 314	Def_000258835	Communication between AHCA and EOG regarding planned communications about June 2022 GAPMS and 59G-1.050(7) - 8/22/2022	X		Objection: Relevance
Pls' Trial Ex. 315	Def_000258833	SMMC Policy Transmittal draft regarding non-coverage of gender dysphoria treatments – August 22, 2022	X		Objection: Relevance
Pls' Trial Ex. 316	Def_000258839	AHCA Medicaid Health Care Alert regarding prohibition on coverage for gender affirming care	X		Objection: Relevance

Pls' Trial Ex. 317	Def_000274 811	AHCA draft response to media regarding gender affirming care – 9/1/2022	X		No Objections
Pls' Trial Ex. 318	Def_000289 978	List of appeals for denials of hormone therapy – 12/19/2022	X		No Objections
Pls' Trial Ex. 319	Def_000290 022	List of requests for surgery to treat gender dysphoria – 12/19/2022	X		No Objections
Pls' Trial Ex. 320	Def_000272 295	AHCA After the Fact Request form for Quentin Van Meter – 6/13/2022	X		No Objections
Pls' Trial Ex. 321	Def_000241 592	AHCA After the Fact Request form for Andre Van Mol – 5/26/2022	X		No Objections
Pls' Trial Ex. 322	Def_001551 590	Draft of welcome/opening remarks for July 8th rule hearing		X	No Objections
Pls' Trial Ex. 323	Def_001511 705	Endocrine Society public comment	X		No Objections
Pls' Trial Ex. 324	Def_001514 249	Yale public comment	X		No Objections
Pls' Trial Ex. 325	Def_001511 606	American Academy of Pediatrics public comment	X		No Objections
Pls' Trial Ex. 326	Def_001551 644	Florida Medicaid, Comment Summary for Rule 59G-1.050 (20 pages)		X	No Objections
Pls' Trial Ex. 327	Def_001551 664	Florida Medicaid, Comment Summary for Rule 59G-1.050 (17 pages)	X		No Objections
Pls' Trial Ex. 328	Def_000296 892	Email communication between Van Mol and Weida and attachment	X		No Objections

Pls' Trial Ex. 328A	Def_000296892-1	Email communication between Van Mol and Weida and attachment	X		No Objections
Pls' Trial Ex. 329	Def_000290414	Florida Medicaid & G/TAT, Andrea Van Mol – May 2022	X		No Objections
Pls' Trial Ex. 330	Def_000286954	GAPMS – Specially Modified Foods	X		Objection: Lack of Foundation, Relevance, Hearsay
Pls' Trial Ex. 331	Def_000286961	GAPMS – Scleral Contact Lenses	X		Objection: Relevance
Pls' Trial Ex. 332	Def_000286947	GAPMS – Fractional Exhaled Nitric Oxide	X		Objection: Relevance
Pls' Trial Ex. 333	Def_000286931	GAPMS – Breast Pump	X		Objection: Relevance
Pls' Trial Ex. 334	Def_000291815	Email from Miriam Grossman – July 7, 2022	X		No Objections
Pls' Trial Ex. 335	EOG_002522	Proposed media response from Brock Juarez to Taryn Fenske – 8/29/2022	X		No Objections
Pls' Trial Ex. 336	Def_000178126	Order striking Van Meter	X		Objection: Relevance, Lack of Foundation
Pls' Trial Ex. 337	Def_001593749	Email communication between Van Meter and AHCA Counsel	X		No Objections
Pls' Trial Ex. 338	Def_000288298	AHCA Microsoft Teams Meeting Invite	X		No Objections
Pls' Trial Ex. 339	Def_002883110	Email communication between Van Meter and Jason Weida	X		Objection: Lack of Foundation, Relevance, FRE 106

Pls' Trial Ex. 340	Def_000237603	AHCA Van Meter Invoice	X		No Objections
Pls' Trial Ex. 341	FDOH_000020148	HCA Hearing on General Medicaid Policy	X		No Objections
Pls' Trial Ex. 342	Def_000239790	Email communication between Devona Pickle and Van Meter	X		No Objections
Pls' Trial Ex. 343	Def_000292237	Email communication between consultants, counsel, and Van Meter	X		No Objections
Pls' Trial Ex. 344	EOG_002234	AHCA Teams Meeting Invites	X		No Objections
Pls' Trial Ex. 344A	EOG_002281	AHCA Teams Meeting Invites	X		No Objections
Pls' Trial Ex. 345	GROSSMAN_0058	Email communication between AHCA and consultants	X		No Objections
Pls' Trial Ex. 346	Def_001572839	Email communication between Sheeran and Brignardello-Petersen		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 347	Def_000296980	Email communication between Van Mol and Weida		X	No Objections
Pls' Trial Ex. 348	Def_002883392	Van Mol comments to Alstott letter		X	No Objections
Pls' Trial Ex. 349	Def_000296946	Email communication between Weida Van Meter, Van Mol and Grossman		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 350	Def_000296905	Email communication between Cantor and Weida		X	No Objections
Pls' Trial Ex. 351	PLAINTIFFS007541	*Sex Differences in Verbal Fluency during Adolescence*, 2013 Soleman		X	Objection: Lack of Foundation, Hearsay

Pls' Trial Ex. 352	PLAINTIFF S007550	Oestrogens are Not Related to Emotional Processing, Soleman 2016		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 353	PLAINTIFF S007557	*Puberty suppression and executive functioning*, 2015 Staphorsius		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 354	PLAINTIFF S007560	*Alterations in the inferior fronto-occipital fasciculus*, van Heesewijk		X	Objection: Lack of Foundation, Hearsay
Pls' Trial Ex. 355	PLAINTIFF S005435	Spreadsheet summarizing Florida Medicaid coverage	X		No Objections
Pls' Trial Ex. 356	PLAINTIFF S003379	DOJ, Dear State Attorneys General Letter re Transgender Youth (March 31, 2022)		X	No Objections

APPENDIX 4

Defendants' Exhibit List

Trial Exhibit Number	Exhibit Description	Will Use	May Use	Stipulated/Plaintiffs' Objections
DX1	U.S. Health and Human Services Notice and Guidance on Care	X		Stipulated
DX2	U.S. Health and Human Services Fact Sheet on Gender-Affirming Care	X		Stipulated
DX3	U.S. Department of Justice Letter to State Attorneys General	X		Stipulated
DX4	Centers for Medicare and Medicaid Services Decision Memo for Gender Dysphoria and Gender Reassignment Surgery	X		Stipulated
DX5	Florida Department of Health Fact Sheet on Treatments for Gender Dysphoria	X		Stipulated
DX6	Florida Medicaid Generally Accepted Professional Medical Standards Determination on the Treatment of Gender Dysphoria (with attachments)	X		§ 802 Hearsay**; For the attachments: § 802 hearsay within hearsay; § 702 improper expert opinions

Trial Exhibit Number	Exhibit Description	Will Use	May Use	Stipulated/Plaintiffs' Objections
DX7	Sweden's Care of Children and Adolescents with Gender Dysphoria	X		§802 hearsay; §602 lack of personal knowledge; §403 relevance; §901 authentication; §1003.33 lacks translation certificate**
DX8	Sweden's Care of Children and Adolescents with Gender Dysphoria, Summary of National Guidelines	X		§802 hearsay; §602 lack of personal knowledge; §403 relevance; §901 authentication; §1003.33 lacks translation certificate**
DX9	Finland's Recommendation of the Council for Choices in Health Care in Finland	X		§802 hearsay; §602 lack of personal knowledge; §403 relevance; §901 authentication; §1003.33 lacks translation certificate**
DX10	The Cass Review, Independent Review of Gender Identity Services for Children and Young People	X		§802 hearsay; §602 lack of personal knowledge; §403 relevance; §901 authentication
DX11	National Institute for Health and Care Excellence, Evidence Review: Gonadotrophin Releasing Hormone Analogues for Children and Adolescents with Gender Dysphoria	X		§802 hearsay; §602 lack of personal knowledge; §403 relevance; §901 authentication

Trial Exhibit Number	Exhibit Description	Will Use	May Use	Stipulated/Plaintiffs' Objections
DX12	National Institute for Health and Care Excellence, Evidence Review: Gender-Affirming Hormones for Children and Adolescents with Gender Dysphoria	X		§802 hearsay; §602 lack of personal knowledge; §403 relevance; §901 authentication
DX13	France's Academie Nationale de Medecine Press Release	X		§802 hearsay; §602 lack of personal knowledge; §403 relevance; §901 authentication; §1003.33 lacks translation certificate
DX14	The Royal Australian and New Zealand College of Psychiatrists' Position Statement on Gender-Affirming Care	X		§802 hearsay; §602 lack of personal knowledge; §403 relevance; §901 authentication
DX15	UKOM Report: Patient Safety for Children and Young People with Gender Incongruence	X		§802 hearsay; §602 lack of personal knowledge; §403 relevance; §901 authentication
DX16	WPATH Standards of Care, Version 8*	X		Stipulated
DX17	WPATH Standards-of-Care-Revision Team Criteria*	X		Stipulated
DX18	WPATH's Press Release Regarding Florida Department of Health *		X	Stipulated

Trial Exhibit Number	Exhibit Description	Will Use	May Use	Stipulated/Plaintiffs' Objections
DX19	WPATH's Statement of Opposition to Florida Draft Rule Banning Gender Affirming Care for Adolescents*		X	Stipulated
DX20	WPATH's Press Release on National and International Issues*		X	Stipulated
DX21	WPATH's Letter to Japanese Officials*		X	Stipulated
DX22	WPATH's Press Release Regarding *New York Times* Article*		X	Stipulated
DX23	WPATH Press Release on United Kingdom Matter*		X	Stipulated
DX24	Endocrine Society Guidelines on Treatments for Gender Dysphoria*	X		Stipulated
DX25	Grading of Recommendations Assessment, Development and Evaluation Handbook*	X		Stipulated

Trial Exhibit Number	Exhibit Description	Will Use	May Use	Stipulated/Plaintiffs' Objections
DX26	American Academy of Pediatrics, Ensuring Comprehensive Care and Support for Transgender and Gender-Diverse Children and Adolescents*		X	Stipulated
DX27	[Intentionally Left Blank]			
DX28	Jonas Ludviggson et al., A Systematic Review of Hormone Treatment for Children with Gender Dysphoria and Recommendations for Research		X	Stipulated

* [Note from Defendants] Note that the State includes the asterisked documents, which either come from or pertain to WPATH, the Endocrine Society, and medical organizations, in the event that the court denies the State's omnibus motion in limine, Doc.126. The State still maintains that such documents, and all mention of or reliance on the organizations, should be excluded at trial.

** [Note from Plaintiffs] To the extent that these documents appear also on Plaintiffs' exhibit list they were listed purely for purposes of rebuttal and/or

impeachment and Plaintiffs object to the introduction of them in the first instance as noted above.